Lymphoproliferative Disorders  >>  luminespib (AUY922)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
luminespib (AUY922) / Ligand
NCT01485536: A Study of the HSP90 Inhibitor AUY922

Terminated
2
21
US
AUY922
M.D. Anderson Cancer Center, Novartis
Lymphoma
11/15
11/15

Download Options